Clover Health Investments (7QD) Ratios
0 Followers
Clover Health Investments Ratios
DE:7QD's free cash flow for Q3 2026 was $69.48M. For the 2026 fiscal year, DE:7QD's free cash flow was decreased by $-898.00K and operating cash flow was $70.38M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.47 | 1.61 | 1.64 | 1.45 | 2.02 |
| Quick Ratio | 1.47 | 1.61 | 1.64 | 1.45 | 2.02 |
| Cash Ratio | 0.37 | 0.91 | 0.45 | 0.24 | 0.81 |
| Solvency Ratio | -0.36 | -0.17 | -0.74 | -0.75 | -1.43 |
| Operating Cash Flow Ratio | -0.32 | 0.16 | -0.44 | -0.47 | -0.76 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 75.55M | $ 103.53M | $ 143.69M | $ 173.26M | $ 341.06M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.01 | 0.01 | 0.03 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.02 | 0.02 | 0.05 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.02 | 0.02 | 0.05 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 |
| Financial Leverage Ratio | 1.75 | 1.70 | 1.99 | 2.27 | 1.78 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | -29661.71 | -184.91 | -33.68 |
| Interest Coverage Ratio | 0.00 | 0.00 | -29332.71 | -210.32 | -37.67 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.01 | 0.02 | 0.10 |
| Net Debt to EBITDA | 0.93 | 4.33 | 0.54 | 0.39 | 0.48 |
| Profitability Margins | |||||
| Gross Profit Margin | 18.49% | 26.61% | 20.30% | 9.44% | -5.38% |
| EBIT Margin | -4.45% | -3.37% | -16.67% | -23.09% | -38.78% |
| EBITDA Margin | -4.36% | -3.28% | -16.47% | -22.98% | -38.70% |
| Operating Profit Margin | -4.44% | -3.34% | -16.29% | -26.14% | -43.27% |
| Pretax Profit Margin | -4.45% | -3.37% | -16.67% | -23.22% | -39.93% |
| Net Profit Margin | -4.45% | -3.14% | -16.93% | -30.97% | -39.93% |
| Continuous Operations Profit Margin | -4.45% | -3.37% | -16.67% | -23.22% | -39.93% |
| Net Income Per EBT | 100.00% | 92.96% | 101.53% | 133.38% | 100.00% |
| EBT Per EBIT | 100.02% | 101.13% | 102.35% | 88.81% | 92.27% |
| Return on Assets (ROA) | -15.81% | -7.41% | -37.39% | -41.99% | -61.82% |
| Return on Equity (ROE) | -27.71% | -12.61% | -74.50% | -95.15% | -109.78% |
| Return on Capital Employed (ROCE) | -25.75% | -12.46% | -66.33% | -76.02% | -110.17% |
| Return on Invested Capital (ROIC) | -25.75% | -12.46% | -65.98% | -75.65% | -109.59% |
| Return on Tangible Assets | -15.90% | -7.44% | -37.58% | -43.06% | -62.09% |
| Earnings Yield | -7.04% | -2.79% | -46.48% | -76.71% | -33.56% |
| Efficiency Ratios | |||||
| Receivables Turnover | 12.12 | 14.78 | 14.62 | 6.54 | 13.45 |
| Payables Turnover | 43.31 | 29.11 | 27.02 | 30.61 | 55.15 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 301.38 | 258.36 | 248.04 | 112.14 | 192.32 |
| Asset Turnover | 3.56 | 2.36 | 2.21 | 1.36 | 1.55 |
| Working Capital Turnover Ratio | 16.83 | 9.25 | 7.00 | 3.82 | 7.26 |
| Cash Conversion Cycle | 21.68 | 12.17 | 11.46 | 43.84 | 20.51 |
| Days of Sales Outstanding | 30.11 | 24.70 | 24.97 | 55.77 | 27.13 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 8.43 | 12.54 | 13.51 | 11.93 | 6.62 |
| Operating Cycle | 30.11 | 24.70 | 24.97 | 55.77 | 27.13 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.13 | 0.07 | -0.24 | -0.43 | -0.60 |
| Free Cash Flow Per Share | -0.13 | 0.07 | -0.24 | -0.44 | -0.60 |
| Dividend Paid and CapEx Coverage Ratio | -32.76 | 22.39 | -198.41 | -45.65 | -390.49 |
| Capital Expenditure Coverage Ratio | -32.76 | 22.39 | -198.41 | -45.65 | -390.49 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | -24.85 | -34.80 | -10.15 |
| Operating Cash Flow to Sales Ratio | -0.03 | 0.03 | -0.09 | -0.19 | -0.19 |
| Free Cash Flow Yield | -5.67% | 2.16% | -25.37% | -47.08% | -16.16% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -13.82 | -35.89 | -2.15 | -1.30 | -2.98 |
| Price-to-Sales (P/S) Ratio | 0.63 | 1.13 | 0.36 | 0.40 | 1.19 |
| Price-to-Book (P/B) Ratio | 3.94 | 4.52 | 1.60 | 1.24 | 3.27 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -17.62 | 46.37 | -3.94 | -2.12 | -6.19 |
| Price-to-Operating Cash Flow Ratio | -18.16 | 44.30 | -3.96 | -2.17 | -6.20 |
| Price-to-Earnings Growth (PEG) Ratio | -0.15 | 0.45 | 0.06 | 0.03 | -0.01 |
| Enterprise Value Multiple | -13.56 | -30.02 | -1.67 | -1.37 | -2.60 |
| Enterprise Value | 1.14B | 1.35B | 347.34M | 344.74M | 1.48B |
| EV to EBITDA | -13.56 | -30.02 | -1.67 | -1.37 | -2.60 |
| EV to Sales | 0.59 | 0.98 | 0.28 | 0.31 | 1.01 |
| EV to Free Cash Flow | -16.49 | 40.52 | -2.98 | -1.65 | -5.23 |
| EV to Operating Cash Flow | -16.99 | 38.71 | -3.00 | -1.69 | -5.24 |
| Tangible Book Value Per Share | 0.59 | 0.69 | 0.59 | 0.71 | 1.14 |
| Shareholders’ Equity Per Share | 0.60 | 0.70 | 0.59 | 0.75 | 1.14 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 3.72 | 2.80 | 2.61 | 2.30 | 3.13 |
| Net Income Per Share | -0.17 | -0.09 | -0.44 | -0.71 | -1.25 |
| Tax Burden | 1.00 | 0.93 | 1.02 | 1.33 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.01 | 1.03 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.09 | 0.30 | 0.35 | 0.44 | 0.30 |
| Stock-Based Compensation to Revenue | 0.05 | 0.08 | 0.11 | 0.15 | 0.11 |
| Income Quality | 0.78 | -0.81 | 0.54 | 0.60 | 0.48 |
Currency in USD
